IMNM
Immunome Inc. Health Care Pharmaceutical Preparations Russell 3000
$18.21Close
$2.1BMarket cap
$15.24 – $29.8352-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 21 · weaker than 79% of stocks over 12 months
- Far from its high 39% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
39%
1wk
up 1.2%
price change
1mo
down 15.3%
price change
12-month return
up 14%
market up 11% ·
its own up 5%
F-score
—
— Not assessed
Altman Z
23.82
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.2×
price / book
Earnings yield
down 15.9%
EBIT / enterprise value
Cheaper than
21%
of the market · expensive
Revenue growth
down 23%
year on year
EPS growth
—
latest quarter
Sales growth
down 100%
latest quarter · +0 pts
ROE
down 52%
return on equity
Free cash margin
down 2890%
-$200.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
5.5%
$1.01 a day · 2×ATR $16.19
RS
21 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
0.82
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 75.5% over the year, from 64m to 113m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 23.2% over the year, from $9.0M to $6.9M.
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026+9% vs market2 sessions after results
Financials
- Net -3060%
- Free cash -2890%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $14.0M | $9.0M | $6.9M |
| Operating income | -$12.3M | -$25.2M | -$36.9M | -$109.5M | -$305.8M | -$224.1M |
| Net income | -$17.8M | -$24.7M | -$36.9M | -$106.8M | -$293.0M | -$212.4M |
| Net margin | — | — | — | -762% | -3240% | -3060% |
| Earnings per share | -$5.26 | -$2.14 | -$3.04 | -$5.38 | -$5.00 | -$2.43 |
| Free cash flow | -$12.7M | -$18.3M | -$28.9M | -$8.4M | -$118.0M | -$200.6M |
| Free cash margin | — | — | — | -60% | -1305% | -2890% |
| Cash | $39.8M | $49.2M | $20.3M | $98.7M | $143.4M | $653.5M |
| Long-term debt | $134,000 | — | — | — | — | — |
| Shareholders' equity | $41.3M | $48.2M | $16.7M | $119.9M | $181.2M | $634.3M |
| Shares outstanding | 10.63m | 12.11m | 12.13m | 43.25m | 64.46m | 113.13m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 19, 2025 | Annual ↗ | Dec 31, 2024 | 78d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 28, 2024 | Annual ↗ | Dec 31, 2023 | 88d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 5, 2026 | Material agreement · Unregistered share sale ↗ |
| Aug 11, 2026 | Results ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 12, 2026 | Results ↗ |
| Mar 3, 2026 | Results ↗ |
| Dec 17, 2025 | Other events ↗ |
| Dec 15, 2025 | Regulation FD · Other events ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 6, 2025 | Results ↗ |
| Jun 11, 2025 | Shareholder vote ↗ |
| May 12, 2025 | Results · Other events ↗ |
| Mar 19, 2025 | Results ↗ |